Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer

Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer

Echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion accounts for 3%-5% of non-small cell lung cancer (NSCLC) patients. With the in-depth study of the EML4-ALK driver gene, ALK inhibitors represented by crizotinib have been gradually developed and applied in...

Full description

Bibliographic Details
Main Authors: Shasha WANG, Yuankai SHI, Xiaohong HAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2020-11-01
Series:Chinese Journal of Lung Cancer
Subjects:
anaplastic lymphoma kinase
lung neoplasms
alk inhibitors
drug resistance
prognostic markers
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.44

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.44

Similar Items